ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 04/29/22

The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this event. For further details see: Oligonucleotide-Based Therapeutics Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates from 10:00 a.m. to 1:00 p.m. ET on May 26, 2022, in ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said it dosed the first patients in a phase 2 trial of ARO-ANG3 to treat patients with homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia (FH) is a disorder in which people have elevated low-density lipoprotein (LDL) cho...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). ARO-ANG3 is the company’s inves...

— Visirna Therapeutics, the Joint Venture formed by Arrowhead and Vivo, received an exclusive license in Greater China to four of Arrowhead’s RNAi-based investigational cardiometabolic medicines — Vivo provided an initial investment of $60 million into Visirna ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022. Conference Call and Webcast Details Invest...

Yes, the MMs must have such forecasts, adjusted minute-by-minute each trading day by their upstairs desks’ direct-wire connections to trading desks at billion-$ institutional portfolios. Those forecasts are integral to hedging protections for MMs as they must short shares for a...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 31 st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022 Title: Pharmaco...

My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and a big biotech trade. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping ...

Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022. An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash. ...